文献速递血栓与止血

活化因子XI-抗凝血酶与凝血酶-抗凝血酶复合物对非小细胞肺癌患者静脉血栓栓塞症和死亡的预测

Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancer.
PubMed 文献 · J Thromb Haemost · 2025-03-06

研究纳入719例新诊断非小细胞肺癌(NSCLC)化疗前患者,检测接触系统激活和凝血酶生成生物标志物,前瞻性记录6个月静脉血栓栓塞症(VTE)和死亡。VTE累积发生率11%,死亡率27%。FXIa:AT和TAT是VTE独立危险因素,基于两者构建的评分可区分VTE和死亡高风险患者。

要点

  • 在NSCLC化疗患者中,6个月VTE累积发生率为11%,死亡累积发生率为27%。
  • FXIa:AT(SHR 1.17,95%CI 1.00-1.37)和TAT(SHR 1.28,95%CI 1.10-1.50)是VTE独立危险因素。
  • 基于FXIa:AT和TAT的评分可区分VTE和死亡风险显著更高的患者。

核心结论

  • 发生VTE的NSCLC患者中观察到体内接触通路激活和凝血酶生成升高,基于FXIa:AT和TAT的评分可识别VTE和死亡高风险患者。

研究设计与样本

  • 前瞻性队列研究,纳入719例开始化疗的新诊断NSCLC患者,检测化疗前血浆接触系统激活和凝血酶生成生物标志物。

主要发现

  • 6个月VTE累积发生率为11%,死亡累积发生率为27%。
  • 发生VTE的患者基线FXIa:AT、F1+2和TAT水平高于未发生VTE者。
  • 存活者PKa:AT、FIXa:AT和TAT水平低于非存活者。
  • 多变量分析显示FXIa:AT(SHR 1.17,95%CI 1.00-1.37)和TAT(SHR 1.28,95%CI 1.10-1.50)为化疗期间VTE独立危险因素。
  • 基于FXIa:AT和TAT的评分可区分VTE和死亡风险显著更高的患者。

关键数值与推荐

  • FXIa:AT作为VTE独立危险因素的SHR为1.17(95%CI 1.00-1.37)。
  • TAT作为VTE独立危险因素的SHR为1.28(95%CI 1.10-1.50)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with non-small cell lung cancer (NSCLC) are at high risk of venous thromboembolism (VTE), especially during chemotherapy. Even though the contact system is implicated in the pathogenesis of thrombosis, limited data are available on the role of contact system activation in NSCLC-associated VTE. OBJECTIVES: In a prospective cohort of patients with NSCLC starting chemotherapy, contact system activation and thrombin generation biomarkers were assessed in relation to 6-month VTE occurrence and mortality. METHODS: Prechemotherapy plasma samples of 719 newly diagnosed patients with NSCLC were tested for in vivo biomarkers of contact system activation (ie, kallikrein [pKa]:antithrombin [AT; PKa:AT], activated factor [F]XI:AT [FXIa:AT], FXIa:C1-esterase inhibitor C1Inh [FXIa:C1Inh], activated FIX:AT [FIXa:AT]), and thrombin generation (ie, prothrombin fragment 1+2 [F1+2] and thrombin-antithrombin complex [TAT]). Clinical data, VTE, and mortality were recorded prospectively. RESULTS: The 6-month VTE and mortality cumulative incidences were 11% and 27%, respectively. Basal levels of FXIa:AT complexes, F1+2, and TAT were higher in patients who developed VTE than those in VTE-free patients. Differently, PKa:AT, FIXa:AT, and TAT were lower in survivors than those in nonsurvivors. The multivariable analysis identified FXIa:AT (subdistribution hazard ratio, 1.17; 95% CI, 1.00-1.37) and TAT (subdistribution hazard ratio, 1.28; 95% CI, 1.10-1.50) as VTE-independent risk factors during chemotherapy. A score based on these biomarkers was generated, which was able to discriminate patients at significantly higher rates of VTE and mortality. CONCLUSION: Elevated in vivo contact pathway activation and thrombin generation were observed in patients with NSCLC who developed VTE. Furthermore, a score based on both FXIa:AT and TAT levels was developed to identify those patients at higher risk of VTE and mortality.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Gomez-Rosas P, Nagy M, Spronk HMH, et al. Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancer. J Thromb Haemost. 2025. PMID: 40056983. doi:10.1016/j.jtha.2025.02.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。